Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease
Autore:
Aisen, PS; Marin, DB; Brickman, AM; Santoro, J; Fusco, M;
Indirizzi:
Mt Sinai Sch Med, Dept Psychiat, New York, NY USA Mt Sinai Sch Med New York NY USA ch Med, Dept Psychiat, New York, NY USA
Titolo Testata:
ALZHEIMER DISEASE & ASSOCIATED DISORDERS
fascicolo: 2, volume: 15, anno: 2001,
pagine: 96 - 101
SICI:
0893-0341(200104/06)15:2<96:PTSOHA>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
AMYLOID PRECURSOR PROTEIN; CHLOROQUINE; MODEL; CELLS; DEGRADATION; INHIBITION; ARTHRITIS; SECRETION; ISCHEMIA; MYOPATHY;
Keywords:
inflammation; colchicine; hydroxychloroquine; clinical trial;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
45
Recensione:
Indirizzi per estratti:
Indirizzo: Aisen, PS Georgetown Univ, Med Ctr, Dept Neurol, 1 Bles Bldg,3800 Reservoir Rd NW, Washington, DC 20007 USA Georgetown Univ 1 Bles Bldg,3800 Reservoir Rd NW Washington DC USA 20007
Citazione:
P.S. Aisen et al., "Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease", ALZ DIS A D, 15(2), 2001, pp. 96-101

Abstract

Anti-inflammatory drugs may be useful in the treatment of Alzheimer disease (AD). In preparation for therapeutic trials, we conducted pilot feasibility studies of hydroxychloroquine alone and in combination with colchicine in subjects with AD. A total of 20 subjects with probable AD were treated with hydroxychloroquine 200 mg twice daily for 11 weeks, or hydroxychloroquine 200 mg twice daily plus colchicine 0.6 mg twice daily for 12 weeks; subjects were monitored for adverse medical, cognitive, or behavioral effects. Neither regimen caused adverse effects on cognitive or behavioral assessmentscores. There were no significant side effects in subjects receiving hydroxychloroquine alone; 2 subjects receiving the two drugs together experienced diarrhea. We conclude that these regimens of anti-inflammatory therapy are well tolerated in subjects with AD, indicating the feasibility of large-scale therapeutic trials of these agents.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/01/20 alle ore 14:42:23